Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in Chinese advanced solid tumors and SCLC
NCT04638491Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lurbinectedin in small cell lung cancer (SCLC) and solid tumor (advanced stage), sponsored by Luye Pharma Group. Primary endpoint: Objective Response Rate up to 12 months. Started Nov 2020; status: completed.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04638491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04638491.